Ascendis Pharma A/S (NASDAQ:ASND) Shares Bought by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 7.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,283,207 shares of the biotechnology company's stock after purchasing an additional 162,079 shares during the period. Price T Rowe Associates Inc. MD owned approximately 3.76% of Ascendis Pharma A/S worth $314,330,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ASND. Capital International Investors lifted its holdings in Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after acquiring an additional 753,859 shares during the period. Avoro Capital Advisors LLC grew its stake in Ascendis Pharma A/S by 2.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after acquiring an additional 114,167 shares during the period. FIL Ltd raised its position in shares of Ascendis Pharma A/S by 13.9% during the 4th quarter. FIL Ltd now owns 729,275 shares of the biotechnology company's stock worth $100,399,000 after purchasing an additional 89,016 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Ascendis Pharma A/S by 17.5% in the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock worth $56,072,000 after acquiring an additional 60,548 shares during the last quarter. Finally, Silverarc Capital Management LLC raised its position in shares of Ascendis Pharma A/S by 929.8% in the fourth quarter. Silverarc Capital Management LLC now owns 51,491 shares of the biotechnology company's stock valued at $7,089,000 after buying an additional 46,491 shares during the last quarter.

Analyst Ratings Changes

ASND has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research note on Tuesday, February 18th. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Cantor Fitzgerald increased their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. Finally, Evercore ISI upped their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of "Moderate Buy" and an average target price of $204.67.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock traded down $3.57 during trading hours on Thursday, hitting $166.87. The company had a trading volume of 266,915 shares, compared to its average volume of 488,606. The company's 50-day moving average is $154.57 and its two-hundred day moving average is $139.68. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $173.25. The company has a market cap of $10.17 billion, a P/E ratio of -23.52 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.